Nuvalent has a Cash Ratio of 20.70. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Nuvalent's Cash Ratio or its related term are showing as below:
NUVL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.69 Med: 22.62 Max: 32.79
Current: 22.62
During the past 5 years, Nuvalent's highest Cash Ratio was 32.79. The lowest was 0.69. And the median was 22.62.
NUVL's Cash Ratio is ranked better than 94.95% of 1526
companies
in the Biotechnology industry
Industry Median: 2.85
vs NUVL: 22.62
Nuvalent Cash Ratio Historical Data
The historical data trend for Nuvalent's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvalent's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvalent's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvalent's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Nuvalent's Cash Ratio falls into.
Nuvalent Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Nuvalent's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvalent (NAS:NUVL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Nuvalent Cash Ratio Related Terms
Thank you for viewing the detailed overview of Nuvalent's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVL has been successfully added to your 